Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes

Diabetic Medicine

Volumn 22, Issue 5, 2005, Pages 654-657

  Lindsay, J R ^a   Duffy, N A ^b   McKillop, A M ^b   Ardill, J ^c   O'Harte, F P M ^b   Flatt, P R ^b   Bell, P M ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Dipeptidyl peptidase IV; GLP 1; Metformin; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DOSE RESPONSE; DRUG DEGRADATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HORMONAL THERAPY; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANTIGENS, CD26; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 17844374375     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01461.x     Document Type: Article

References (13)

1. Meier JJ, Gallwitz B, Nauck MA. Glucagon-like peptide 1 and gastric polypeptide: potential applications in type 2 diabetes mellitus. Biodrugs 2003; 17: 93-102.
2. O'Harte FPM, Gault VA, Parker JC, Harriott P, Mooney MH, Bailey CJ, Flatt PR. Improved stability, insulin-releasing activity and anti-diabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide. N-Acetyl-GIP Pglu-GIP. Diabetologia 2002; 45: 1281-1291.
3. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem, 1993; 214: 829-835.
4. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Invest Drugs 2003; 12: 87-100.
5. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rotella CM. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 2001; 24: 489-494.
6. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24: 720-725.
7. Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Sarki T, Tanaka I. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophy Res Commun 2002; 298: 779-784.
8. Fujiwara K, Tsuru D. New chromogenic and fluorogenic substrates for pyrrolidonyl peptidase. J Biochem 1978; 83: 1145-1149.
9. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am 1997; 26: 523-537.
10. Zarghi A, Faroutan SM, Shafaati A, Khoddam A. Rapid determination of metformin in human plasma using ion-pair HPLC. J Pharmaceut Biomed Anal 2002; 31: 197-200.
11. Hinke SA, Kunh-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth H-U. Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-1308.
12. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002; 51: 1461-1469.
13. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.